Condition: HER2-negative Breast Cancer Patients With Brain Metastases · Sponsor: Biostar Pharma, Inc.
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receive treatment of utidelone alone or in combination with capecitabine. The objectives both in stage I and stage II are to evaluate the intracranial and systemic efficacy and safety of utdelone plus capecitabine for the treatment of HER2-negative breast cancer patients with brain metastases.
This description comes directly from the study's public registry record.
Simon Guan · +86 10 67864938 · simon.guan@biostar-pharma.com
Always discuss trial participation with your own doctor first.
| City of Hope--Duarte | Duarte, California, United States | Not Yet Recruiting |
| Cancer & Blood Research Center, LLC | Los Alamitos, California, United States | Recruiting |
| Univ. of California Los Angeles | Los Angeles, California, United States | Not Yet Recruiting |
| FOMAT Medical Research (Network) | Oxnard, California, United States | Recruiting |
| Scripps Health | San Diego, California, United States | Recruiting |
| University Of Colorado Hospital - Anschutz Cancer Pavilion | Aurora, Colorado, United States | Recruiting |
| Biosresearch Partner | Hialeah, Florida, United States | Recruiting |
| D&H Cancer Research Center | Margate, Florida, United States | Recruiting |
| Augusta University | Augusta, Georgia, United States | Recruiting |
| Robert H. Lurie Comprehensive Cancer Center Northwestern University | Chicago, Illinois, United States | Recruiting |
| The Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine | Baltimore, Maryland, United States | Not Yet Recruiting |
| Profound Research LLC | Farmington Hills, Michigan, United States | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06764940